康寧傑瑞製藥-B(09966.HK):控股股東家族信託重組
格隆匯4月21日丨康寧傑瑞製藥-B(09966.HK)公佈,董事會於2023年4月21日接獲劉陽、徐氏家族信託及新徐氏家族信託通知,已就家族財富繼承計劃目的進行下列重組步驟:
(a) 於2023年4月10日,新徐氏家族信託成立,其中劉陽作為委託人及保護人;
(b) 於2023年4月20日,徐氏家族信託的分配顧問行使權力,向劉陽(以徐氏家族信託受益人的身份)授予對徐氏家族信託的信託基金指定權;及
(c) 於2023年4月21日,劉陽行使其對徐氏家族信託的信託基金指定權,將Rubymab的100%股權自徐氏家族信託的信託基金指定予受託人(以新徐氏家族信託受託人的身份)。
緊隨重組完成後,(i) Rubymab由受託人(以新徐氏家族信託受託人的身份)全資擁有;(ii)劉陽通過新徐氏家族信託及Rubymab於公司已發行股本總額的約32.55%中擁有權益;及(iii)徐博士為新徐氏家族信託的受益人及投資顧問,且截至公吿日期繼續持有公司已發行股本總額的約0.47%。
由於新徐氏家族信託於重組完成後收購公司已發行股本總額的約32.55%,因而劉陽(作為新徐氏家族信託的委託人及保護人)控制公司30%或以上投票權,故已向執行人員申請豁免劉陽因重組而對公司所有股份提出強制性全面收購要約的責任;就此,執行人員已根據收購守則規則26.1註釋6(a)豁免劉陽提出全面收購要約。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.